Navigation Links
Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies
Date:12/12/2008

NEW YORK, Dec. 12 /PRNewswire-FirstCall/ -- In his last public remarks as the leader of a large biopharmaceutical company, Sidney Taurel, chairman of Eli Lilly and Company (NYSE: LLY), today said that the promise of personalized medicine won't become a reality unless markets and regulatory environments encourage and reward companies for the long-term, expensive research required to move innovative new products from the lab bench to the bedside.

Taurel, who will retire on December 31, after nearly 40 years in health care, today addressed an audience at the Center for Medical Progress of the Manhattan Institute in New York City.

"I firmly believe that we stand on the cusp of an unprecedented period of discovery and invention in the life sciences, in which our understanding of individual human differences replaces our pursuit of generalized wellbeing as the main driver of medical progress," said Taurel.

Taurel said that the gap between medicine as an art and a true science may finally be closing. The decoding of the human genome has energized hopes for truly personalized medicine.

"Today, there is hardly a molecule or an approved product anywhere in Lilly's pipeline or portfolio that is not the subject of tailoring. Our goal is to give doctors the ability to prescribe for individual patients -- with a much higher level of confidence -- the right dose of the right medicine and the right time."

"Early progress at Lilly makes clear that personalized medicine is no illusion," said Taurel. "However, personalized medicine also is not guaranteed."

Taurel cautioned that policies that may be expedient in the short-term -- like weakened patent protections for biotech medicines, price controls for new drugs, or new regulatory hurdles between innovators and the marketplace -- will slow the pace of innovation and leave future patients exposed to the ravages of cancer and Alzheimer's longer than necessary.

"Innovation in life sciences depends on these set of basic requirements that seem perpetually under threat in political debates and policy deliberations," Taurel said. "Many of these approaches fly in the face of personalized medicine -- from slowing the progress for future innovation to reducing the range of options available to doctors and patients."

Taurel offered three areas of policy innovation -- private and public -- that might progress medical innovation and improve human health, including increasing personal choice and tapping health information. He labeled the third policy area as simply "working together."

"No single company, industry, agency, or even nation will add very much to improving human health by working on its own," said Taurel. "Rather, accelerating the development of new medicines will depend on collaboration, flexibility and trust. The same openness and spirit of partnership will be required in our relationships with patients and doctors."

"The canvas of human health looks vastly better than today than it did when I began my career in the early 1970s. And I remain convinced that it will look much better still -- from the vantage point of another generation -- with many more of the details filled in by the artists of personalized medicine," concluded Taurel.

About Lilly

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. C-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Lilly Global Day of Service Receives National and Local Recognition
2. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
3. Lilly Completes Acquisition of ImClone Systems
4. Lilly Receives NCQA Health Information Product Certification for Interactive Online Health Education Answers Program
5. Lilly Offers Free Health Guide, Available throughout State
6. Lilly and International Council of Nurses Win Partnership Award From the U.S. Chamber of Commerce Business Civic Leadership Center
7. Lilly Announces Major Donation of Insulin to International Diabetes Federations Life for a Child Program; Initial Focus Will Be on Sub-Saharan Africa
8. American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes
9. Teach For America and Lilly Launch Program to Match Lilly Employees with Teachers in Underserved Public Schools
10. Lilly to Sponsor Congressional Black Caucus Foundations Annual Legislative Conference
11. Lilly Set to Become First Pharmaceutical Research Company to Disclose Physician Payments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Sessions in Dallas that it will receive two significant new grants to support ... as PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists ...
(Date:6/24/2016)... ... ... of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum Wage’ ... 2020 and then adjusting it yearly to increase at the same rate as the median ... floor does not erode again, and make future increases more predictable. , The company is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: